Press Releases

Personalis, Inc., a leader in advanced genomics for cancer, announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical trial assay (CTA) based on the Personalis® NeXT Platform™, an exome/transcriptome scale NGS-based assay, to support development of BGB-3245, an investigational next-generation B-RAF inhibitor, in patients with advanced o

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phas

Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect of monoclonal antibodies that block this signaling in preclinical models. IL-11, a member of the IL-6 family of cytokines, is a c

Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research w

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. The SARS-CoV-2 NGS Assay is an in vitro diagnostic test, a highly sensitive nucle

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1/2 clinical trial of EO2463, a potential treatment for indolent non-Hodgkin B-cell lymphomas (iNHL). EO2463 will be Enterome's second OncoMimics candidate to ente

Zenas BioPharma ("Zenas") launched today as a cross-border biopharmaceutical company committed to being a global leader in developing and delivering immune-based therapies to patients in China and China to become worldwide. Founded and funded initially by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds Management LLC (“Fairmount”), Zenas is also supported by a group of leading global investment funds in the life sciences including Quan Capita

Selexis SA, a JSR Life Sciences company, and Tallac Therapeutics have signed both a commercial license agreement (CLA) and a service agreement (SA) to advance Tallac’s Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform, which harnesses the power of innate and adaptive immunity to treat cancer. Under the agreements, Tallac will employ Selexis’ proprietary SUREtechnology Platform™ to develop the research cell banks necessary to bring its immunotherapy candidates fo

Stelis Biopharma (Stelis) today announced that it has successfully concluded its Series B and Series C fund raise for a cumulative amount of US$ 195m. Post money valuation for Stelis will be pegged at ~US$ 350m, underpinning the significant growth potential of the business. With the current capital raise, Stelis is now well-positioned to pursue its growth initiatives and scale its business model to deliver promising returns in the coming years.        

The Japanese pharmaceutical market is preparing for renewed international growth and partnering. In response, CPhI Japan has opened a two-month long virtual event to meet demand from international pharma. Informa introduced CPhI Japan Connect – a new virtual platform for global professionals looking to grow pharma business in Japan – specifically to help its international audiences continue conversations, identify leads, and build new partnerships while international tra